2025-12-31 - Analysis Report
Here's a breakdown of the TEM (Tempus AI Inc.) stock data, along with analysis.

**0. Overview**

*   **Ticker:** TEM
*   **Company:** Tempus AI Inc.
*   **Overview:** Tempus AI is a technology company focused on precision medicine through data and artificial intelligence.

**1. Return Rate Comparison (TEM vs. S&P 500)**

*   **TEM Cumulative Return:** 7.80%
*   **VOO (S&P 500) Cumulative Return:** 31.44%
*   **Divergence:** -20.5
*   **Relative Divergence:** 17.5 (This means the current divergence is in the bottom 17.5% of the divergence range seen historically).

**Analysis of Alpha, Beta, CAGR, MDD:**

*   **CAGR (2023-2025):** 8.0% - Moderate growth over the period.
*   **MDD (2023-2025):** 76.7% -  Extremely high Maximum Drawdown. This indicates significant price volatility and risk.
*   **Alpha (2023-2025):** -23.0% - Underperformed the market on a risk-adjusted basis.
*   **Beta (2023-2025):** 0.3 -  Relatively low Beta. Suggests low volatility. This seems contradictory to the MDD. It is likely that the Beta is low due to idiosyncratic risks and the stock not trending with the market.
*   **Cap (B):** 10.7B -  Indicates a relatively large market capitalization.

**2. Recent Stock Price Fluctuations**

*   **Current Close:** $60.39
*   **Previous Close:** $61.47
*   **Change:** -$1.76
*   **5-day SMA:** $62.71
*   **20-day SMA:** $69.16
*   **60-day SMA:** $77.99

**Analysis:** The stock is trading below its 5-day, 20-day, and 60-day moving averages. This suggests a short-term downward trend.

**3. Indicator Analysis**

*   **MRI:** 0.9 (Medium Investment Recommended)
*   **RSI:** 16.19 (Oversold)
*   **PPO:** -1.03
*   **Hybrid Signal:** "cash_0%_Buy 100% of cash (14 shares - Very Safe - MRI:0.90)" - Model suggests buying the stock.
*   **Recent Relative Divergence Change:** -2.8 (Indicates a short-term decline in relative performance compared to the S&P 500)
*   **Expected Return (%):** NaN (Not Available)

**Analysis:**

*   **RSI:** The stock is significantly oversold, which *could* indicate a potential for a rebound.
*   **MRI:** Indicates medium market risk, supporting the buy conclusion of the Hybrid Signal.
*   **Recent Divergence Change:** Confirms a recent underperformance relative to the S&P 500.
*   **Expected Return:** The NaN value is concerning. This could be due to insufficient data or high uncertainty in future projections.

**4. Recent News & Significant Events:**

*   **Positive (AI Focus):**  Several articles highlight Tempus AI's position to benefit from the AI boom in MedTech and its potential for scaling.
*   **Mixed/Cautionary:**  Articles discuss a "pivotal transition," near-term risks, and debate whether the stock is a buy, hold, or sell. One article compares TEM to HIMS. The Yahoo article warns it is a pivotal transition.
*   **Positive (Price Uptick):** One article notes the stock is up 87% in 2025.
*   **FDA:** Mentions potential issues regarding FDA clearance.
*   **Drop:** Mentions a stock drop, a concerning sign.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 2.14)
*   **Target Price:** Average: $88.92, High: $105.00, Low: $80.00
*   **Recent Rating Changes:** None reported.

**Analysis:** Analysts are generally positive on the stock with an average target price significantly above the current price.

**5. Comprehensive Analysis**

*   **Summary:** Tempus AI (TEM) has significantly underperformed the S&P 500 in 2023-2025. While the stock is currently oversold (RSI), and analysts have a "Buy" consensus with substantial upside target prices, there are significant risks to consider. The very high MDD reflects major volatility.  The lack of an expected return is concerning.
*   **News Impact:** Recent news paints a mixed picture. The focus on AI in MedTech and potential for scale are positive. The news also point to transition phases and stock drops, showing concerns.
*   **Investment Recommendation (Based on this limited data):** The current situation is **HIGHLY RISKY**. While the Hybrid Signal suggests a buy based on a medium-risk indicator (MRI of 0.9), the underperformance relative to the S&P 500, extremely high MDD, lack of expected return data, and warning of transition phase suggest extreme caution.
*   **Further Investigation:** Before investing, investigate the following:
    *   Reasons for the high Maximum Drawdown.
    *   The details of the "pivotal transition" mentioned in the news.
    *   The FDA clearance issues mentioned in the news.
    *   Why the "Expected Return (%)" is showing as NaN.
    *   The financial health of Tempus AI, particularly its cash burn rate and path to profitability.
    *   The reasons for the negative Alpha value.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.